New immunotherapy combo shows promise for tough childhood cancer

NCT ID NCT03786783

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding two immunotherapy drugs (dinutuximab and GM-CSF) to standard chemotherapy is safe and doable for children newly diagnosed with high-risk neuroblastoma. Forty-two children took part. The goal was to see if the extra drugs cause too many side effects or prevent patients from getting enough doses. The approach aims to help the immune system fight the cancer better while shrinking tumors before a stem cell transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GANGLIONEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027, United States

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania, 15224, United States

  • Children's National Medical Center

    Washington D.C., District of Columbia, 20010, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

    New York, New York, 10032, United States

  • Primary Children's Hospital

    Salt Lake City, Utah, 84113, United States

  • Royal Children's Hospital

    Parkville, Victoria, 3052, Australia

  • Saint Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

  • Starship Children's Hospital

    Grafton, Auckland, 1145, New Zealand

  • The Children's Hospital at Westmead

    Westmead, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.